<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1616">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04513964</url>
  </required_header>
  <id_info>
    <org_study_id>READCARDIOCOVID</org_study_id>
    <nct_id>NCT04513964</nct_id>
  </id_info>
  <brief_title>Impact of COVID-19 on the Benefit of Cardiac Rehabilitation</brief_title>
  <acronym>REACARDIOCOVID</acronym>
  <official_title>Impact of COVID-19 on the Benefit of Cardiac Rehabilitation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Groupe Hospitalier Paris Saint Joseph</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Groupe Hospitalier Paris Saint Joseph</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The COVID-19 attack is polymorphic with otorhinolaryngological, pneumological, cardiac,
      digestive, neurological, muscular attacks with a higher mortality in subjects with
      comorbidity [&gt; 70 years old, cardiovascular history in particular Arterial hypertension
      (hypertension ), heart disease…]. This polymorphism is linked to vasculitis and the immune
      response.

      Patients with cardiovascular disease are particularly at risk of decompensating, particularly
      due to the increased metabolism induced by viral infection and reduced cardiovascular
      capacities.

      On the cardiovascular level, two sides can be considered. On the one hand, cardiovascular
      disease (hypertension, coronary artery disease) is a comorbid factor. On the other hand, the
      myocardial damage reflected by the increase in troponin or an alteration of the ejection
      fraction is a very clear risk factor for death or severe form.

      Cardiovascular involvement is particularly high in hospitalized and deceased patients. The
      odds ratio calculated in a meta-analysis of severe forms of covid-19 with hypertension is 3
      [1.9; 3.1], for cardiovascular pathologies of 2.93 [1.73; 4.96]. Recommendations were made
      for pulmonary rehabilitation but not for cardiovascular rehabilitation.

      Cardiac rehabilitation is indicated in most cardiovascular pathologies (after acute coronary
      syndrome, after coronary angioplasty, in heart failure, after coronary or valve heart
      surgery, etc.).

      It consists of a multidisciplinary approach combining therapeutic pharmacological adjustment,
      physical activity, therapeutic education in order to improve physical capacities for exertion
      and reduce morbidity and mortality. The physical exercises can be endurance or resistance
      type.

      Capacity gain at the end of rehabilitation is measured by visual scales, quality of life
      questionnaires, and a stress test at the start and end of rehabilitation. Most often,
      rehabilitation centers only do the stress test and estimate through questioning for
      subjective improvement.

      The hypothesis is that patients who contracted COVID-19 would have lower cardiac capacities
      after recovery from the infection than patients without COVID-19 or that their capacity for
      recovery would be less. There could be a difference in recovery after cardiac rehabilitation
      between the two populations regardless of whether the cardiac damage requiring rehabilitation
      was triggered by COVID-19 or was pre-existing.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Impact of COVID-19 on exercise capacity gain after cardiovascular rehabilitation</measure>
    <time_frame>Month 3</time_frame>
    <description>This outcome corresponds to the difference between the average gain in exercise capacity after cardiac rehabilitation between the two groups of patients Control and COVID-19.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Heart Failure</condition>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>Patient not suffering from COVID-19</description>
  </arm_group>
  <arm_group>
    <arm_group_label>COVID-19</arm_group_label>
    <description>Patient who has been infected with COVID-19 with suggestive signs and authentication by PCR or thoracic CT or serology</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        This study will be carried out on the data of patients referred for outpatient
        cardiovascular rehabilitation in one of the participating centers between 02/01/2020 and
        12/31/2020, patients affected or not by COVID-19, i.e. around 60 patients in total.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient aged ≥ 18 years

          -  Patient referred for outpatient cardiovascular rehabilitation in one of the
             participating centers between 02/01/2020 and 12/31/2020

          -  French-speaking patient

        Exclusion Criteria:

          -  Patient under guardianship or curatorship

          -  Patient deprived of liberty

          -  Patient under legal protection

          -  Patient objecting to the use of their data as part of this research
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>DUC Philippe, MD</last_name>
    <role>Study Director</role>
    <affiliation>Groupe Hospitalier Paris Saint Joseph</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>DUC Philippe, MD</last_name>
    <phone>0144127883</phone>
    <phone_ext>+33</phone_ext>
    <email>pduc@ghpsj.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>BEAUSSIER Helene, PharmD, pHD</last_name>
    <phone>0144127883</phone>
    <phone_ext>+33</phone_ext>
    <email>crc@ghpsj.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital Corentin Celton</name>
      <address>
        <city>Issy-les-Moulineaux</city>
        <zip>92130</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Iliou Marie-Christine, MD</last_name>
      <email>marie-christine.iliou@aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <results_reference>
    <citation>Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11. Erratum in: Lancet. 2020 Mar 28;395(10229):1038. Lancet. 2020 Mar 28;395(10229):1038.</citation>
    <PMID>32171076</PMID>
  </results_reference>
  <results_reference>
    <citation>Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, Ma K, Xu D, Yu H, Wang H, Wang T, Guo W, Chen J, Ding C, Zhang X, Huang J, Han M, Li S, Luo X, Zhao J, Ning Q. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ. 2020 Mar 26;368:m1091. doi: 10.1136/bmj.m1091. Erratum in: BMJ. 2020 Mar 31;368:m1295.</citation>
    <PMID>32217556</PMID>
  </results_reference>
  <results_reference>
    <citation>Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24. Erratum in: Lancet. 2020 Jan 30;:.</citation>
    <PMID>31986264</PMID>
  </results_reference>
  <results_reference>
    <citation>Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y, Wang X, Peng Z. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020 Mar 17;323(11):1061-1069. doi: 10.1001/jama.2020.1585.</citation>
    <PMID>32031570</PMID>
  </results_reference>
  <results_reference>
    <citation>Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, Li YM, Liu XQ, Chen RC, Tang CL, Wang T, Ou CQ, Li L, Chen PY, Sang L, Wang W, Li JF, Li CC, Ou LM, Cheng B, Xiong S, Ni ZY, Xiang J, Hu Y, Liu L, Shan H, Lei CL, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Cheng LL, Ye F, Li SY, Zheng JP, Zhang NF, Zhong NS, He JX; China Medical Treatment Expert Group for COVID-19. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J. 2020 May 14;55(5). pii: 2000547. doi: 10.1183/13993003.00547-2020. Print 2020 May.</citation>
    <PMID>32217650</PMID>
  </results_reference>
  <results_reference>
    <citation>Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, Gong W, Liu X, Liang J, Zhao Q, Huang H, Yang B, Huang C. Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. JAMA Cardiol. 2020 Jul 1;5(7):802-810. doi: 10.1001/jamacardio.2020.0950.</citation>
    <PMID>32211816</PMID>
  </results_reference>
  <results_reference>
    <citation>Young BE, Ong SWX, Kalimuddin S, Low JG, Tan SY, Loh J, Ng OT, Marimuthu K, Ang LW, Mak TM, Lau SK, Anderson DE, Chan KS, Tan TY, Ng TY, Cui L, Said Z, Kurupatham L, Chen MI, Chan M, Vasoo S, Wang LF, Tan BH, Lin RTP, Lee VJM, Leo YS, Lye DC; Singapore 2019 Novel Coronavirus Outbreak Research Team. Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore. JAMA. 2020 Apr 21;323(15):1488-1494. doi: 10.1001/jama.2020.3204.</citation>
    <PMID>32125362</PMID>
  </results_reference>
  <results_reference>
    <citation>Lippi G, Lavie CJ, Sanchis-Gomar F. Cardiac troponin I in patients with coronavirus disease 2019 (COVID-19): Evidence from a meta-analysis. Prog Cardiovasc Dis. 2020 May - Jun;63(3):390-391. doi: 10.1016/j.pcad.2020.03.001. Epub 2020 Mar 10. Review.</citation>
    <PMID>32169400</PMID>
  </results_reference>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 13, 2020</study_first_submitted>
  <study_first_submitted_qc>August 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 14, 2020</study_first_posted>
  <last_update_submitted>August 13, 2020</last_update_submitted>
  <last_update_submitted_qc>August 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

